





Wednesday, May 2 and Thursday, May 3, 2007

---

P R O G R A M







## *Table of Contents*

Welcome Letter	3
About the Foundation	4
About Diabetes	6
Strategic Partnership	8
Research	10
Breakthroughs	12
Celebrity Participants	24
Thank You	26

THE IACocca FAMILY





May 2, 2007

Welcome to Las Vegas! We are so happy you have decided to join us. Our family is grateful to everyone who has traveled to this amazing resort to participate in the Iacocca Celebrity Golf Tournament, our signature event for 2007. We have two great days planned in the desert – from all the members of the Iacocca family, thank you for being here.

We'd also like to recognize our friends Steve and Elaine Wynn, who have gone above and beyond the call in serving as our hosts. They've opened up their doors – and golf course – so that we can get together and raise funds for vital diabetes research. We're also grateful for our corporate support, especially from our Title Sponsor, DaimlerChrysler Corporation. DaimlerChrysler has been with us since the beginning of our JoinLeeNow fundraising efforts, and is nearing \$5 million in support. Their commitment to our cause is second to none.

And we'd be remiss if we didn't thank all of the celebrities who have chosen to be here with us as well. We recognize the demands placed on celebrities and acknowledge those who are with us for the tournament.

The Iacocca Foundation has been supporting diabetes research for over 23 years now, and will continue to do so until there's a cure. The Iacocca Celebrity Golf Tournament could not have happened without all of you, so please accept our sincere thanks for joining us at Wynn Las Vegas. Together we'll find a cure for this disease. Enjoy your stay in Las Vegas and good luck in the tournament.

Warm regards,

Lee Iacocca

Kathryn Iacocca Hentz

Lia Iacocca Assad

## About The Iacocca Foundation



In 1984, Lee A. Iacocca established The Iacocca Foundation in honor of his late wife, Mary K. Iacocca, who died from complications of type 1 diabetes. Drawing on the expertise and drive demonstrated through his illustrious 40-year career in the automotive business, Lee dedicated the Foundation's mission to funding innovative and promising diabetes research programs and projects that will lead to a cure and alleviate complications caused by the disease.

Lee's daughter Kathryn also became actively involved with the cause, becoming the Foundation's president; Kate was later joined by her sister Lia as a trustee. Under the guidance of the family, dedicated trustees and extraordinary financial and science advisors, the Foundation has funded more than \$26 million in promising research projects since its inception.

### Our Mission

Understanding the power of private philanthropy the family has focused on providing funding for the brightest and best minds in diabetes research. Forming long-lasting relationships with a diverse and dedicated team, The Iacocca Foundation has been successful in funding years of discoveries while at the same time providing financial support for over 115 Iacocca Fellows.

### The Breakthrough

During the first two decades all funding was provided by Foundation-generated funds until a major breakthrough by long time funded researcher Dr. Denise Faustman at the Massachusetts General Hospital in 2003. Building on an earlier discovery in 2001, Dr. Faustman was the first diabetes researcher that proved if the underlying cause of type 1 diabetes could be stopped, regeneration of the insulin producing cells could, and did, occur.

Motivated by Lee's promise to his wife Mary to cure the disease in his lifetime, the Foundation launched JoinLeeNow in 2004. The goal of this campaign was originally to raise additional funding to translate Dr. Faustman's project from research to reality. Today JoinLeeNow continues to raise money for other regeneration projects and focuses on providing critical funds to accelerate research from the lab to people living with diabetes.



## Until There's a Cure

The Iacocca Foundation has matured to be one of this country's leading diabetes research funders. The knowledge the family and its team of dedicated trustees and advisors bring to the research arena allows researchers to test the impossible. Thanks to our supporters we look forward to providing more funding; we feel strongly that with advancing technology and years of accumulated science, we are closer than ever before to finding a cure.

### **Accelerating The Pace And Promise Of Diabetes Research For More Than 20 Years...**

Since its inception, the Foundation has funded more than \$26 million in cutting edge diabetes research.

Each year the Foundation provides seed money, almost \$2 million annually, to the brightest and best diabetes researchers ensuring new solutions are in development.

The Foundation prioritizes projects that address how to stop the cause of diabetes without the need of immunosuppression or other invasive therapies.

In an amazing breakthrough in 2001, a longtime IF-funded researcher, Dr. Denise Faustman, proved for the first time that if the autoimmune attack was stopped, regeneration of the beta cells in the pancreas could, and did, occur.

In 2004 The Iacocca Foundation's JoinLeeNow campaign was created to take promising research to human clinical efforts.

Since its inception JoinLeeNow has raised over \$8.7 million, granted \$3 million in 2006 and is committed to \$4.4 million in 2007.

## About Diabetes

The story of diabetes spans over 3,500 years. With the significant discoveries and breakthroughs of a long list of medical pioneers including Paul Langerhans, Elliot Joslin, Claude Bernard and today's dedicated researchers, much progress has been made toward the understanding and treatment of the disease. But today, this lifelong disease continues to challenge the patients and families who are affected by it.



### One Name – Two Different Diseases

Nearly 40 years ago we learned that diabetes is one word, but two different diseases:

**Type 1 diabetes**, or insulin-dependent disease, is an autoimmune disorder characterized by the inability to produce insulin, the enzyme necessary to metabolize sugar. As a result, sugar cannot move from the blood into cells, causing blood sugar to rise above a safe level and leaving cells without the ability to function properly. Once diagnosed with the disease, patients must carefully control their blood sugar levels for the rest of their lives with daily monitoring and insulin injections in conjunction with diet control and regular exercise.

Type 1 diabetes increases the risk of a number of health complications, including accelerated heart disease, blindness, stroke, amputation, nerve damage, and kidney damage.

**Type 2 diabetes**, or non-insulin dependent disease, is the most common form of diabetes - accounting for 90% of cases. It is linked with insulin deficiency or resistance where the body does not produce enough insulin or the cells ignore the insulin, causing a buildup of sugar in the blood. In most cases, the disease is managed with lifestyle modifications, including diet control and exercise. However, over time, patients will become insulin dependent – leaving them with the same projected lifespan and risk of complications as those with type 1 disease.

Associated complications are similar to those of type 1, including cardiovascular disease, blindness, nerve damage, and kidney damage. Disturbingly, type 2 diabetes - traditionally called adult-onset diabetes-is being diagnosed in increasingly younger children.

## A National Epidemic

Our nation is facing a diabetes epidemic with approximately 20 million people - a staggering 7% of the population - with diabetes. Nearly one-third of these people are unaware they have diabetes. And these numbers are growing. The incidence of both type 1 and type 2 disease has multiplied over the past twenty years, due in part to the increasingly sedentary lifestyle of Americans. Prediabetes, or glucose intolerance, a precursor to type 2 disease, is also at epidemic proportions, affecting approximately 16 million Americans.

## Working Toward a Cure

Although, a cure for diabetes has not yet been found, great strides have been made in treating the disease and improving the quality of life for those living with it. As innovative projects and dedicated researchers - supported by the great amount of money raised for and invested in diabetes research - continue to expand our knowledge, the promise of a cure seems closer every day.

## AN EPIDEMIC AT A GLANCE

More than 240 million people worldwide are presently living with diabetes. Estimates are that the number will grow to 380 million within the next 20 years...

One in every 400 to 600 American children and adolescents has type 1 diabetes...

Seven percent of the US population, over 20.8 million individuals, is living with diabetes...

6.2 million Americans are unaware that they have the disease...


Diabetes is responsible for serious and life threatening complications including heart disease, stroke, high blood pressure, kidney disease, amputation, dental disease and more...

One out of every 10 health care dollars spent in the US is spent on diabetes and its complications...

Even though the complications from the disease, and not the disease itself, are often listed as a patient's cause of death, diabetes still ranks as the sixth leading cause of death among Americans...



## Joslin Diabetes Center



Early efforts of the Iacocca Foundation included a partnership with Joslin Diabetes Center in Boston, Massachusetts. Joslin is the only diabetes institution in the world that goes beyond a single focus, to research, care, and education. With efforts in these three critical areas, a synergy develops; researchers, clinicians and educators collaborate in ways that produce cutting-edge scientific discovery, unique clinical care models and pioneering educational strategies.

Over time The Iacocca Foundation has created five strategic endowments at Joslin which provide almost \$1 million annually in diabetes support for Joslin researchers.

# strategic partnership

**Mary K. Iacocca Research Fellowship Fund**, established in 1981 to support a research fellowship on an annual basis in the Elliot P. Joslin Research Laboratory.

**Mary K. Iacocca Professor of Medicine and Director of Research**, established in 1986 through Harvard Medical School to create the Mary K. Iacocca Chair in Medicine in the field of diabetes and metabolism. The chair is held by diabetes expert Dr. C. Ronald Kahn.

**Mary K. Iacocca Director of the Laboratory of Advanced Genetic Technologies**, established in 1991 to support Joslin's research programs, 'Diabetes and the Genome,' and fund the Mary K. Iacocca Director of the Laboratory of Advanced Genetic Technologies. More recently, this fund has supported several labs that have initiated advanced genetic techniques, such as genomics and proteomics, as part of the Iacocca Genome Project.

**Mary K. Iacocca Senior Visiting Research Fellowship**, established in 1994, this fellowship is designed to attract visiting senior scientists from around the globe to Joslin encouraging collaboration into alternate fields of science, medicine and engineering to introduce new ideas and technologies to diabetes research.

**Mary K. Iacocca Faculty Fellowship**, established in 1999 to bring "highly skilled" individuals who are not already in the field of diabetes to work and study along with senior faculty members at Joslin for one year.



**University of Massachusetts Medical School  
Dr. Aldo Rossini  
Heat Shock Proteins in the  
Pathogenesis of Type 1 Diabetes**

Dr. Aldo Rossini has brought together a number of scientists from diverse disciplines to investigate novel proteins involved in the pathogenesis of autoimmune type 1 diabetes. They have identified a protein that has previously been unknown to be involved in insulin secretion and are also developing a humanized mouse model to study the relationship of the development of insulin producing cells and the human immune system.



**Georgetown University Medical Center  
Dr. Maja Maric  
Identification of GILT-Specific  
Small Inhibitory Molecule**

With the use of Iacocca funding, Dr. Maja Maric aims to inhibit the continued destruction of insulin producing cells to benefit both diabetics at an early stage of the disease, and patients that have received islet transplants. Maric's lab, in collaboration with a colleague, Dr. Ostrov at the University of Florida, is using a computer algorithm to identify potential molecules that will be developed as drug therapy to slow down or stop the self-destruction of insulin producing cells in the pancreas by autoimmune T-cells, thus allowing the function of the pancreas to be preserved.

Each year the Foundation provides seed money,  
almost \$2 million annually, to the brightest and best  
diabetes researchers

# research



**Boston Children's Hospital  
Dr. Morris White  
Identification of Drugs that  
Promote Regeneration of Human Islets**

Dr. Morris White is utilizing his funding from The Iacocca Foundation to create molecules that will be developed as drug therapy to increase the synthesis of a particular protein (IRS2) in human insulin producing cells. Dr. White believes that this will promote the regeneration and survival of the insulin producing cells, thereby preventing and eliminating diabetes.



**Baylor College of Medicine  
Dr. Lawrence Chan  
Induced Islet Neogenesis to  
Reverse Type 1 Diabetes**

Dr. Chan and his team of researchers developed a new therapy that essentially 'cures' type 1 diabetes in mice. Through gene therapy, Chan's lab was able to induce the growth of new insulin producing cells in the livers of diabetic mice. These new cells produce enough insulin to maintain a normal blood sugar level, initiating total recovery from chemical-induced diabetes in mice. Iacocca funding will enable Dr. Chan to take his research to the next step and develop a therapy capable of reversing autoimmune diabetes in mice that has the potential of being translated into a cure for type 1 diabetes in humans.



**Dr. Karen Peterson  
Coast to Coast Initiative to Prevent  
and Control Childhood Obesity  
Funded in partnership with The Rosalinde and  
Arthur Gilbert Foundation**

The Coast to Coast Initiative to Prevent and Control Childhood Obesity (C2C) is a partnership with Harvard University School of Public Health, Center for Weight and Health at the University of California, Berkeley, WGBH, the Public Broadcasting System affiliate in Boston, MA, Samuels and Associates in California and Mathematica Policy Research.

Conceived as a multidisciplinary approach to addressing the obesity crisis in elementary and middle school-aged children nationwide, this initiative will implement, evaluate and disseminate a comprehensive intervention for school districts to use to control and prevent obesity in children and, by extension, their families. Although C2C draws upon previous research in this field, this initiative is unique in that it brings together many current best practices with the objective of surrounding children with coordinated programs and policies to promote healthy eating and physical activity.



**Massachusetts General Hospital, Diabetes Unit**  
**Dr. Denise Faustman**

With over ten years support of The Iacocca Foundation Dr. Denise Faustman's lab successfully cured end stage diabetic mice and proved for the first time that cell regeneration was possible in the field of diabetes. This unprecedented publication in 2001 gave new hope to those living with diabetes.

By eliminating the cause of type 1 diabetes through a two drug combination therapy, Dr. Faustman was able to permanently restore normal blood glucose levels by regenerating insulin producing cells in the pancreas. Today Dr. Faustman's lab is developing new blood tests and automating this cutting-edge technique in preparation for a phase one human clinical trial in 2008.

breakthrough



**University of Virginia, Diabetes and Hormone Center of Excellence  
Dr. Jerry L. Nadler**

Dr. Nadler's project is focused not only on stopping the autoimmune attack but also addresses how to expedite the regeneration of insulin producing cells. Based on publication that the combination of a beta growth factor called exendin-4 and another drug lysofylline (LSF) have been successful in reversing established type 1 diabetes in the mouse model, Dr. Nadler is currently reformulating the drug LSF for more efficient use as a therapy in humans. This project is expected to be moving forward with a clinical trial to test the safety and effectiveness of this therapy in the next year.

nroughs

DAIMLERCHRYSLER CORPORATION  
IS VERY PROUD TO HAVE RAISED \$4.7 MILLION  
IN SUPPORT OF THE IACOCCA FOUNDATION.  
THANKS, LIDO. WE'RE PROUD TO BE ON YOUR TEAM.



**CHRYSLER**



THE CHRYSLER 300C